MET and neoplasm: Rilotumumab (AMG102) is a fully human neutralizing monoclonal antibody against HGF that potently inhibited the growth of GBM-derived cell lines such as U87 MG, which has HGF/Met autocrine signaling, in culture and in tumor xenografts as a single agent.